Related Experiment Videos
Coronary vascular changes in the progression and regression of hypertensive heart disease
B E Strauer1, B Schwartzkopff, W Motz
1Medical Clinic B, University of Düsseldorf, Germany.
Insights
Hypertension can impair coronary blood flow due to small vessel changes, especially in patients with left ventricular hypertrophy. Pharmacotherapy can reverse these changes, potentially preventing heart failure.
Area of Science:
- Cardiology
- Hypertension Research
- Vascular Biology
Background:
- Hypertension is linked to coronary hemodynamic alterations.
- Left ventricular hypertrophy (LVH) in hypertension can affect myocardial oxygen supply.
- Small coronary vessel abnormalities may contribute to cardiac dysfunction.
Purpose of the Study:
- To analyze coronary hemodynamics in experimental and clinical hypertension.
- To investigate the role of small coronary vessel medial hypertrophy in hypertensive LVH.
- To evaluate the impact of pharmacotherapy on coronary reserve and vascular structure.
Main Methods:
- Analysis of coronary hemodynamics, including blood flow, coronary reserve, and myocardial oxygen consumption.
- Assessment of medial hypertrophy and wall thickness/radius ratio in small coronary vessels.
- Evaluation of changes after long-term pharmacotherapy.
Main Results:
- Hypertensive patients with LVH exhibited significantly reduced coronary reserve.
- Medial hypertrophy of small coronary vessels correlated with impaired coronary flow.
- Pharmacotherapy led to normalization of medial hypertrophy and coronary reserve.
- Small vessel abnormalities correlate with clinical findings like angina in hypertensive heart disease.
Conclusions:
- Small coronary vessel hypertrophy is a key factor in impaired coronary flow in hypertensive LVH.
- This microcirculation disorder may contribute to late cardiac failure in hypertension.
- Pharmacological reversal of LVH and vascular smooth muscle hypertrophy offers a potential strategy for preventing heart failure.
Abstract:
Coronary hemodynamics (blood flow, coronary reserve, myocardial oxygen consumption) were analyzed in both experimental and clinical hypertension. Significantly reduced coronary reserve was found in hypertensive patients with left ventricular hypertrophy. Medial hypertrophy of small coronary vessels associated with a marked increase in the wall thickness/radius ratio was considered sufficient to explain the impaired coronary flow in hypertensive left ventricular hypertrophy. After long-term pharmacotherapy, there was normalization of both medial hypertrophy and coronary reserve. This small-vessel abnormality correlates well with clinical findings in hypertensive heart disease (angina and electrocardiographic changes despite normal coronary arteriogram). Moreover, this structural adaptation of the small vessels may carry the inherent risk of an impaired oxygen supply to the hypertrophied myocardium. Thus, late cardiac failure of the hypertrophied heart in hypertension may be attributed, in part, to this microcirculation disorder. Conversely, reversal of left ventricular hypertrophy and of hypertrophy of vascular smooth muscle by specific pharmacotherapy can be considered a possible rational approach to the prevention of cardiac failure in hypertensive patients. Controlled clinical trials are needed to confirm these findings with regard to prevention of heart failure, and pharmacotherapeutic studies are necessary to define the optimal drug regimen for reversal of vascular smooth muscle hypertrophy.